Birabresib (OTX-015, MK-8628) is an experimental small molecule inhibitor of BRD2, BRD3, and BRD4 under investigation for the treatment of cancer. It is in development by Merck & Co. It is currently in clinical trials for leukemia and glioblastoma.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.